ANRO — Alto Neuroscience Share News
0.000.00%
Last trade - 00:00- $887.66m
- $662.58m
U.S. STOCKS ON THE MOVE-Hims & Hers Health, Microstrategy, FedEx
U.S. STOCKS ON THE MOVE-Block, Constellation Energy, Dollar General
Alto Neuroscience gains on depression drug acquisition deal
Brief: Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights
Brief: Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business Highlights
Brief: Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker
Brief: Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder Trial
Brief: Alto Neuroscience Files For Mixed Shelf Of Up To $300 Million
Brief: Alto Neuroscience Amends Loan And Security Agreement
U.S. STOCKS ON THE MOVE-Alphabet, Boeing, Arcadium Lithium
Brief: Alto Neuroscience Initiates Phase 2 Study Of Alto-101 In Cognitive Impairment Associated With Schizophrenia
Brief: Alto Neuroscience Announces Initiation Of Phase 2 Study Of ALTO-203 In Patients With Major Depressive Disorder
U.S. RESEARCH ROUNDUP-Agiliti, Domino's Pizza, Krystal Biotech